Description

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C23H43F3N6O7—-[1]Lu A, et al. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011 Jun;178(6):2573-86.|[2]Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98.—-572.62–99.84–O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N)=O)=O)=O)[C@H](CO)N.OC(C(F)(F)F)=O–Cancer–H2O : 125 mg/mL (ultrasonic)–Others—-Others–Peptides